Current studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing significant outcomes in addressing weight gain and diabetes 2 disease. Preclinical data suggest a distinct process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/